Navigation Links
New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
Date:7/6/2009

LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget of nearly 6 million euros.

The new consortium, formed by Syncom, Synvolux Therapeutics, and University Medical Center Groningen, focuses on designing a versatile drug delivery system for inflammatory diseases and cancer. Another new consortium is formed by InteRNA Technologies, Utrecht University and VU University Medical Center, and focuses on the development of anti-angiogenic microRNA-based therapeutic products for the treatment of cancer.

Versatile drug delivery platform for inflammatory diseases and cancer

New molecular entities (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation might circumvent side effects and improve their general therapeutic efficacy. However, currently, no appropriate formulation technology is available for these kinase inhibitors.

This project focuses on a systematic approach in which chemical modification of NMEs is combined with drug formulation studies. This will lead to a versatile drug delivery platform for future clinical application of kinase inhibitors in the treatment of cancer and chronic inflammatory diseases. "This approach is expected to make targeted drug delivery finally meet its expectations, as it will become available for a variety of drug classes that are under development in the pharmaceutical industry," according to the consortium members.

Development of novel anti-angiogenic miRNA based therapeutics

"Conventional cancer treatment such as surgery, radiation therapy and chemotherapy are
'/>"/>

SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
2. Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)
3. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
4. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
7. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
9. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
10. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ewswire/ -- NexBio Inc., in collaboration with sci...vention (CDC), St. Louis University, and the Unive...n of two articles in the peer-reviewed journal PLo...AS181 (Fludase ® ) may play a potentially imp...e Pandemic Influenza A(H1N1) and drug-resistant in...
(Date:11/5/2009)...5 Osteotech, Inc. (Nasda...ogic products for regenerative healing, today repo... September 30, 2009. ,, "During the third quart...ree new biologic products MagniFuse(TM) Bone Graf...74; Innovative Grafting," said Sam Owusu-Akyaw, Pr...
(Date:11/5/2009)...PRNewswire/ -- ARKRAY, Inc., the world,s 5th large...s, today announced that it has received 510(k) cle...r its new GLUCOCARD Vital blood glucose monitoring...hich ARKRAY will make available for distribution i...complement to the existing GLUCOCARD line of produ...
Breaking Medicine Technology:NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than 55398 1Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than 55398 2Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than 55398 3Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than 55398 4Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 1Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 2Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime Anywhere Access to Patient Data and Communications 55393 3Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA 28TM 29 in the U S 55388 1Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA 28TM 29 in the U S 55388 2Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA 28TM 29 in the U S 55388 3Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA 28TM 29 in the U S 55388 4
...erseon, Inc.,( http://www.inverseon.com ) announce... trial in asthma., In the article by Hanania et a... 21, (2008), pp. 134-141, entitled, "The safety an...thma: An open-label pilot,study," mild asthmatics ...he drug, and 8 of 10 subjects experienced a clinic...
...0 Pharma (N30), a,biopharmaceutical company focuse...tion of respiratory drugs that target endogenous,s...sfully completed Phase 1,study of N30-201 in healt...the treatment of reactive and obstructive airway d...We are pleased to have begun and completed the fir...
Other Medicine Technology:Inverseon Announces Positive Phase IIa Asthma Study 2
(Date:11/6/2009)...6 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (... will report financial results for the third quart...ay, November 9, 2009. Cardiome will hold a telecon... Pacific) on that day to discuss the results. ,, T...7806 or 888-789-9572 and reference conference 2345...
(Date:11/6/2009)... & Lymphoma Society (LLS) will again be partic...h in its first two campaigns this past spring and ...LS,s blood cancer research funding and patient edu...n, taking place from November 12th to 15th, Gap In... participants can use (in-store only) at all Gap ...
(Date:11/6/2009)... urgent message to the U.S. House of Representativ... in debate over procedures related to abortion and...eting to discuss proposed amendments to the bill, ... permit discussion of "an amendment to keep in pla...science protections." Some in the House seek a "cl...
(Date:11/6/2009)...rganizations specializing in infectious diseases p... expressing their significant concern with current...rotective equipment (PPE) by healthcare workers in...1 influenza. The Society for Healthcare Epidemio...ciety of America (IDSA) and the Association for Pr...
(Date:11/6/2009)...o by, researcher says , , FRIDAY, Nov. 6 (...le with multiple sclerosis who have relapses withi...kely to suffer from severe limitations in the shor...ngs, published Nov. 4 in Neurology , show that pe...s of developing it are nearly 50 percent more like...
Breaking Medicine News(10 mins):Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2Health News:Early Relapse of MS May Mean Fewer Issues Later 2
...th Staphylococcal,HIV, Tuberculosis and Other Infe...pitalized,patients for drug-resistant infections c...educe cost of care, according to a new report rele...,physicians to adjust medications or take other st...
...rgest Hope Lodge in,New York City, NEW YORK, Marc...enges. Finding an affordable, supportive place to ...ancer Society is pleased to,announce its newest an...t., the Hope Lodge,in Manhattan meets an urgent, p...
...r shamans and herb women? Not at all, for many che...cine are natural products or were developed on the...n prostate and breast cancer treatment are made fr... example, against malignant lymphomas. The modern ...
...on Against This Leading Cause...ording to the national,nonprofit, Home Safety Coun...use of home injury death in the United States. Yet...home safety concern,proving the need for aggressiv...
...hairman and Chief Executive Officer of Met-Pro Cor...pany,s Systems Division has received an,order to s... to a major,pharmaceutical company in the Northeas...the Company,s current fiscal,year., Working with ...
...ol? You may want to schedule a few appointments wi...e about how to shape up your eating habits, accord...ichigan Health System researchers. , Not only ar...e already taking one. And youll probably lose weig...
Other Medicine News:Health News:Hospital Testing for Drug-Resistant Infections Dramatically Lowers Mortality Rates and Costs 2Health News:American Cancer Society to Open Doors to Its New Free Lodging and Support Center in NYC for Cancer Patients and Caregivers 2Health News:Screening the herbal pharmacy 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 3Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 4Health News:Met-Pro Corporation's Systems Division Receives Equipment Order Totaling Approximately $600,000 2Health News:Met-Pro Corporation's Systems Division Receives Equipment Order Totaling Approximately $600,000 3Health News:Study shows cholesterol-lowering power of dietitian visits 2Health News:Study shows cholesterol-lowering power of dietitian visits 3Health News:Study shows cholesterol-lowering power of dietitian visits 4
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: